Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Gains from Investment Securities (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Gains from Investment Securities over the past 16 years, most recently at -$7.6 million for Q2 2025.

  • Quarterly results put Gains from Investment Securities at -$7.6 million for Q2 2025, down 293.51% from a year ago — trailing twelve months through May 2025 was -$4.9 million (down 166.36% YoY), and the annual figure for FY2025 was -$7.8 million, down 325.38%.
  • Gains from Investment Securities for Q2 2025 was -$7.6 million at Lifecore Biomedical, Inc. \De\, down from -$275000.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for LFCR hit a ceiling of $2.4 million in Q4 2024 and a floor of -$7.6 million in Q2 2025.
  • Median Gains from Investment Securities over the past 5 years was $36500.0 (2023), compared with a mean of -$344062.5.
  • Biggest five-year swings in Gains from Investment Securities: surged 5354.55% in 2024 and later crashed 1048.28% in 2025.
  • Lifecore Biomedical, Inc. \De\'s Gains from Investment Securities stood at $428000.0 in 2021, then plummeted by 120.09% to -$86000.0 in 2022, then surged by 151.16% to $44000.0 in 2023, then surged by 5354.55% to $2.4 million in 2024, then tumbled by 415.96% to -$7.6 million in 2025.
  • The last three reported values for Gains from Investment Securities were -$7.6 million (Q2 2025), -$275000.0 (Q1 2025), and $2.4 million (Q4 2024) per Business Quant data.